logo

Myovant Sciences Ltd (MYOV)



Trade MYOV now with
  Date
  Headline
7/6/2020 8:34:35 AM Myovant Sciences Presents Additional Data On Relugolix Combination Therapy From Phase 3 LIBERTY Studies
6/23/2020 7:41:16 AM Myovant Sciences Announces Positive Results From Second Phase 3 Study Of Relugolix Combination Therapy
6/22/2020 8:40:21 AM Myovant Sciences: FDA Accepts For Priority Review Of NDA For Relugolix For Advanced Prostate Cancer
5/29/2020 8:16:14 AM Myovant Sciences Announces Addl Positive Efficacy And Cardiovascular Safety Data From Phase 3 HERO Study
4/21/2020 8:39:47 AM Myovant Sciences Submits NDA To FDA For Once-Daily, Oral Relugolix For Men With Advanced Prostate Cancer